Delayed-onset, grade IV neutropenia associated with rituximab therapy in a lymphoma patient: A case report and literature review No significant financial relationships to disclose. This is an ASCO ...
Phase III Study to Evaluate Efficacy and Safety of Andecaliximab With mFOLFOX6 as First-Line Treatment in Patients With Advanced Gastric or GEJ Adenocarcinoma (GAMMA-1) In a phase III, US intergroup ...
Erythropoietin treatment improves brain function, neuropsychological test scores, and electroencephalography measurements in patients with CKD. Both chronic kidney disease (CKD) and anemia may ...
Company will issue ordinary shares and pay $10 million upon successful Phase II trial of rHuEPO. XTL Biopharmaceuticals entered into an asset purchase agreement with Bio-GAL for the rights to a use ...
The FDA previously updated the boxed warning for all erythropoiesis-stimulating agents (darbepoetin [Aranesp], epoetin alfa (Epogen, Procrit]) because of increased risk of serious and life-threatening ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results